Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGASUS: Ga68-MAA PET/CT for Lung Function Preservation in SBRT
NCT04942275Phase 3Unknown
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Jul 2021
- Primary completion
- Jul 2022
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gallium 68 macroaggregated albumin in non-small cell lung cancer (NSCLC) and cancer, sponsored by Centre Hospitalier Universitaire de Brest. Primary endpoint: Patients with a dose reduction to the functional lung at 1 week. Status: unknown.
02
Drugs
gallium 68 macroaggregated albumin
03
Conditions
non-small cell lung cancer (NSCLC)cancer
Beyond the preview
Go deeper on NCT04942275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04942275.